Status:
COMPLETED
A Study to Determine the Optimal Tolerated Regime and Safety of PEP005 Topical Gel
Lead Sponsor:
Peplin
Conditions:
Actinic Keratoses
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine the optimal tolerated regime of PEP005 for the treatment of actinic keratoses of the face or face and scalp.
Detailed Description
Actinic keratoses (AK) is a common skin condition characterized by rough, scaly patches or sores on the top layer of the skin which if left untreated can progress to skin cancer. Current treatments ca...
Eligibility Criteria
Inclusion
- Male patients at least 18 years of age.
- Post-menopausal female patients i.e., no menses for at least 12 consecutive months, or without a uterus.
- Four to eight clinically typical, visible and discrete AK lesions within a contiguous 25 cm2 treatment area on the face or face and scalp.
- 5\. Ability to follow study instructions and likely to complete all study requirements.
- 6\. Written informed consent has been obtained. 7. Agreement from the patient to allow photographs of the selected AK treatment area to be taken and used as part of the study data package.
Exclusion
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2007
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00427050
Start Date
January 1 2007
End Date
November 1 2007
Last Update
September 14 2015
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Skin and Cancer Foundation
Darlinghurst, New South Wales, Australia, 2010
2
Southderm Pty Ltd
Kogarah, New South Wales, Australia
3
St George Dermatology and Skin Cancer Centre
Level 3, 22 Belgrave St, Kogarah, New South Wales, Australia, 2217
4
South East Dermatology
Belmont Specialist Centre, 1202 Creek Rd, Carina Heights, Queensland, Australia, 4152